moxifloxacin has been researched along with Benign Neoplasms in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azéma, J; Dewelle, J; Guidetti, B; Kiss, R; Korolyov, A; Le Calve, B; Malet-Martino, M; Martino, R; Mijatovic, T; Vaysse, J | 1 |
| Baum, C; Bello, CL; Dinolfo, M; Huang, X; Levine, S; Mulay, M; Patyna, S; Rosen, L; Toh, M; Van Vugt, A | 1 |
| Ball, HA; Dar, MM; Heath, EI; Infante, J; Kasubhai, S; Kleha, JF; Lewis, LD; LoRusso, P; Luu, T; Ma, B; Stephenson, J; Suttle, AB; Tan, AR | 1 |
| Slavin, MA; Thursky, KA | 1 |
| Akan, H; Akova, M; Aoun, M; Calandra, T; de Bock, R; Drgona, L; Kern, WV; Marchetti, O; Paesmans, M; Viscoli, C | 1 |
| Frisbee-Hume, S; Ho, DH; LeBlanc, B; Rolston, KV; Streeter, H | 1 |
| Bamias, A; Chamilos, G; Dimopoulos, MA; Efstathiou, E; Kastritis, E; Kostis, E; Papadimitriou, C; Zorzou, PM | 1 |
| Bille, J; Calandra, T; Cometta, A; Kern, WV; Marchetti, O; Zinner, S | 1 |
| Bachelot, T; Biron, P; Chelghoum, M; Chvetzoff, G; Devaux, Y; Dussart, S; Fuhrmann, C; Geoffrois, L; Ghesquieres, H; Lancry, L; Rodrigues, I; Sebban, C | 1 |
4 trial(s) available for moxifloxacin and Benign Neoplasms
| Article | Year |
|---|---|
Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib.
Topics: Antineoplastic Agents; Arrhythmias, Cardiac; Aza Compounds; Dose-Response Relationship, Drug; Electrocardiography; Fluoroquinolones; Granisetron; Heart Ventricles; Humans; Indoles; Moxifloxacin; Neoplasms; Placebos; Protein-Tyrosine Kinases; Pyrroles; Quinolines; Risk; Sunitinib; Time Factors | 2009 |
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors.
Topics: Adult; Aged; Algorithms; Angiogenesis Inhibitors; Anti-Bacterial Agents; Aza Compounds; Blood Pressure; Confidence Intervals; Double-Blind Method; Electrocardiography, Ambulatory; Female; Fluoroquinolones; Heart Conduction System; Heart Rate; Humans; Indazoles; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Neoplasms; Pyrimidines; Quinolines; Sulfonamides; Young Adult | 2013 |
Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectiou
Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Clavulanic Acid; Double-Blind Method; Drug Combinations; Female; Fever; Fluoroquinolones; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Neoplasms; Neutropenia; Quinolines; Risk Factors; Treatment Outcome | 2013 |
Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Aza Compounds; Ceftriaxone; Female; Fever; Fluoroquinolones; Humans; Infusions, Intravenous; Male; Middle Aged; Moxifloxacin; Neoplasms; Neutropenia; Patient Discharge; Quinolines; Risk Factors; Time Factors | 2008 |
5 other study(ies) available for moxifloxacin and Benign Neoplasms
| Article | Year |
|---|---|
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum Tolerated Dose; Mice; Neoplasms; Piperazine; Piperazines | 2009 |
Outpatient therapy for fever and neutropenia is safe but implementation is the key.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Female; Fever; Fluoroquinolones; Humans; Male; Moxifloxacin; Neoplasms; Neutropenia; Quinolines | 2013 |
In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients.
Topics: Anti-Infective Agents; Aza Compounds; Bacterial Infections; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Hospitalization; Humans; Microbial Sensitivity Tests; Moxifloxacin; Neoplasms; Quinolines | 2003 |
Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Aza Compounds; Female; Fever; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Neoplasms; Neutropenia; Quinolines; Risk Assessment; Safety; Treatment Outcome | 2005 |
In vitro antimicrobial activity of moxifloxacin against bacterial strains isolated from blood of neutropenic cancer patients.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Neoplasms; Neutropenia; Quinolines | 2006 |